DoseMe Appoints Sophie Leech as Bioinformatician to Advance Model-Informed Precision Dosing Platform

JUPITER, FL– March 24, 2026

JUPITER, FL– March 24, 2026 – DoseMe, a global leader in model-informed precision dosing (MIPD) software, today announced the appointment of Sophie Leech as Bioinformatician.

As DoseMe expands its platform with the recent addition of Firstline, the role of bioinformatics and advanced data science becomes increasingly critical. Integrating evidence-based antimicrobial guidance with Bayesian precision dosing requires robust model validation, large-scale dataset analysis, and seamless data architecture to ensure accuracy at the point of care.

“Sophie’s combination of computational rigor, clinical pharmacokinetic modeling experience, and large-scale data analysis expertise strengthens our scientific foundation as we continue expanding the DoseMe platform,” said Rick Malone, Vice President, Clinical and Science, DoseMe. “Bioinformatic expertise underpins this convergence, enabling the platform to translate complex pharmacokinetic models, real-world patient data, and clinical decision support logic into a unified, reliable system that supports antimicrobial stewardship, optimizes outcomes, and scales across diverse health system environments.”

In this role, Leech will contribute to the development, implementation, and optimization of pharmacokinetic and data-driven models that power the DoseMe platform.

Leech brings a strong academic and technical background spanning metagenomics, high-performance computing, statistical modeling, and machine learning. She is in her final stages of completing her PhD at The University of Queensland, where her research focuses on human microbiomes in pregnancy and early life. She has published three first-author peer-reviewed papers and presented her work at 10 scientific conferences, earning multiple presentation awards.

“I’m excited to continue contributing to DoseMe’s mission of improving patient outcomes through model-informed precision dosing,” said Leech. “The opportunity to apply advanced computational tools and pharmacokinetic modeling to real-world clinical challenges is incredibly meaningful.”
Leech previously joined DoseMe through an internship, where she supported identification and implementation of pharmacokinetic drug models for inclusion in the platform. Her work included re-estimating parameters of published PK models using Nlmixr2 in R and Stan/Torsten, experimenting with machine learning approaches for a priori model selection, and analyzing a dataset of more than 500,000 patients to evaluate detection of acute kidney injury using vancomycin pharmacokinetic models.
Leech is also active in scientific leadership and community engagement. She served as Treasurer of the Australian Society of Medical Research (Queensland State Committee) and previously held leadership roles within the School of Chemistry and Molecular Biosciences Research Student Social Club, supporting scientific programming and student engagement initiatives.

About DoseMe
DoseMe is the provider of Firstline and DoseMeRx clinical decision support technologies that enable proactive, personalized care.  Firstline is a mobile-first platform making treatment guidance accessible to every clinician, anywhere.  DoseMeRx delivers clinically validated PK/PD models to individualize precision dosing in seconds. DoseMe’s evidence-based clinical intelligence helps reduce adverse drug events, antibiotic overuse, improved adherence to stewardship guidance, and provides clinicians a clear path to optimal care. For more information and real-world success stories, visit https://doseme-rx.com/success-stories